Eli Lilly (LLY) Return on Assets ROA from the second quarter of 2026 to second quarter of 2025 and for the year 2026, Average High and Low, Fundamental Ratios from Jun 30 2026 to Jun 30 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Eli Lilly And Company  (NYSE: LLY)


Eli Lilly's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Eli Lilly's ROA in the second quarter of 2026?
Eli Lilly And Company achieved a return on average assets (ROA) of 21.71 % in its second quarter of 2026, this is above LLY's average return on assets of 10.93%.
Eli Lilly And Companys assets during the 12 months ending in the second quarter of 2026 are valued at $123 billion

ROA decreased relative to the period ending Mar 31 2026, due to the decline in net income.

However, within the Healthcare sector 45 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 191, from total ROA ranking in the first quarter of 2026 at 263.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Total Assets Change 40.9 % 33.9 % 46.36 % 52.02 % 40.41 %
Y / Y Net Income Change 25.34 % 168.04 % 50.52 % 475.34 % 90.78 %
Net Income (TTM) in million 26,711 25,277 20,640 18,412 13,800
Return On Assets (TTM) 21.71 % 22.43 % 19.63 % 19.18 % 16.01 %
LLY's Total Ranking # 191 # 263 # 256 # 316 # 383
Total Assets (TTM) in million 142,197 119,692 115,278 114,936 100,924
Seq. Total Assets Change 18.8 % 3.83 % 0.3 % 13.88 % 12.9 %
Seq. Net Income Change -4.07 % 11.42 % 18.9 % -1.38 % 105.14 %

LLY's 5 Years Annual ROA >> Back to LLY Management Effectiveness >> Compare LLY ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 26
Sector # 46
Overall # 199

Return On Assets Statistics
High Average Low
22.73 %
10.93 %
-7.41 %
(Mar 31 2026)   (Dec. 31, 2008)





Financial Statements
Eli Lilly's Assets $ 142,197 million LLY's Balance sheet
Eli Lilly's Income $ 7,095 million Quarterly LLY's Income Statement
LLY's Income by Division See LLY's Income by Division



Annual Return On Assets (Dec 31 2025)
FY 2025		 (Dec 31 2024)
FY 2024		 (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021
Y / Y Total Assets Change 46.45 % 22.98 % 29.33 % 1.4 % 4.66 %
Total Assets in million 115,278 78,717 64,008 49,491 48,806
Y / Y Net Income Change 94.9 % 102.08 % -16.08 % 11.88 % -9.88 %
Net Income in million 20,640 10,590 5,240 6,245 5,582
Annual Return On Assets 17.9 % 13.45 % 8.19 % 12.62 % 11.44 %

LLY's 5 Years Annual ROA >> Back to LLY Management Effectiveness >> Compare LLY ROA to its Competitors



Comment on LLY's ROA in the fiscal year ending 2025
In the fiscal year 2025 ROA improved to 17.9 % compared to prior year, due to annual net income growth of 94.9 % to $20,640.00 million, while value of Eli Lilly's overall assets grew just by 46.45 % to $115,278.00 million, compared to $115,278.00 a year before.


More Return On Assets Ratios
LLY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
LLY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for LLY's Competitors
Subscribers only: Roa for Eli Lilly's Suppliers
Subscribers only: Return On Assets for LLY's Customers

You may also want to know
LLY's Roi LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons
LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector ROA
Atlantic Coastal Acquisition Corp Ii  54.09 %
Lensar Inc   47.48 %
Elite Pharmaceuticals Inc   46.11 %
Omeros Corporation  46.05 %
Q32 Bio Inc   45.18 %
Aurinia Pharmaceuticals Inc   44.95 %
Agenus Inc  44.86 %
Earth Science Tech Inc   44.02 %
Liquidia Corporation  36.30 %
Ironwood Pharmaceuticals inc   34.34 %
Idexx Laboratories Inc  33.61 %
Tg Therapeutics Inc   33.59 %
Meiragtx Holdings Plc  29.37 %
Indivior Pharmaceuticals Inc   28.21 %
Qhslab Inc   27.12 %
Adma Biologics Inc   26.58 %
Mettler toledo International Inc   24.86 %
Medpace Holdings Inc   24.84 %
Caredx Inc   24.81 %
Acadia Pharmaceuticals Inc   24.38 %
Eli Lilly And Company  21.97 %
Innoviva Inc   21.64 %
Vaxart Inc   20.85 %
Zevra Therapeutics Inc   20.39 %
Iradimed Corporation  20.36 %
Protalix Biotherapeutics inc   20.09 %
Pro dex Inc   19.87 %
Electromed Inc   19.39 %
United Therapeutics Corporation  17.98 %
Resmed Inc   17.80 %

Date modified: 2026-09-12T18:39:21+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.